A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma
NCT ID: NCT01063998
Last Updated: 2013-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
23 participants
OBSERVATIONAL
2009-09-30
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A reliable urinary assay for kidney cancer would have major implications for tumor screening in high risk patients, in selection of patients for adjuvant therapy, in surveillance and prognosis and possibly as a surrogate marker for response to therapy. Human kidney injury molecule-1 (KIM-1) has been found to be a sensitive and specific biomarker in identifying kidney injury. The urine levels of KIM-1 are increased in the patients with kidney failure and major types of kidney tumors. The purpose of the study is investigate how urine KIM-1 and a routine blood marker for renal failure (creatinine) can distinguish kidney tumors from non-tumor kidney injury. The ultimate goal of this project is to develop a simple non-invasive method to screen patients for potential kidney tumors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.
Urine Marker
Urinary KIM-1 measurements
p 2
Patients diagnosed with renal cancer and normal creatinine.
Urine Marker
Urinary KIM-1 measurements
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Urine Marker
Urinary KIM-1 measurements
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
OR
* Patients diagnosed with renal cancer and normal creatinine.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
William Beaumont Hospitals
OTHER
Jason Hafron
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jason Hafron
Chairman, Dept of Urology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason Hafron, MD
Role: PRINCIPAL_INVESTIGATOR
Beaumont Hospitals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beaumont Hospitals
Royal Oak, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-125
Identifier Type: -
Identifier Source: org_study_id